One Medicine, One Payment: How Boehringer Ingelheim Is Closing the Loop on Site Payments
After consolidating 40 systems into one platform, Boehringer Ingelheim's Sarita Thomas explains why site payments was the missing piece...
The Study Build That Used to Take Weeks Now Takes Minutes
Inside Crucial Data Solutions' Floyd AI and the case for synthetic control arms
How 3 Converging Waves (Not Just AI) are Transforming Clinical Data.
The clinical data world has been promised transformation before. With advancements like eSource, risk-based monitoring, and paperless trials, each...
Where Clinical Trials Have Never Been: Rovia’s Case for Building Research Infrastructure in Forgotten Communities
Rovia grew a site network in places where sponsors needed patient access. Now sponsors are coming to him.
The Infrastructure Bet That Pays Off Before the First Patient Enrolls
Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled toolkits in...
Why the First Scan Matters Most: IAG’s Romiesa Hagoug on Keeping Imaging Data Honest Across Multi-Site Trials
Romiesa Hagoug, Head of Project Management at Image Analysis Group (IAG), on what a site's first scan reveals, how...
When the Trial Fails, Was It the Drug or the Design?
NetraMark's Chief Innovation and Regulatory Officer Luca Pani, MD, on why broad enrollment can obscure treatment effects, what makes...
AbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancer
Daejin Abidoye, Vice President, Therapeutic Area Head, Oncology, Solid Tumor and Hematology at AbbVie, discusses new data from ABBV-1480...
When the Trial Ends, the Data Work Begins
Dr. Olga Kubassova, Founder and CEO of Image Analysis Group (IAG), discusses how AI-driven imaging biomarkers extend the value...
When the Scan Knows Before the Spirometer Does
Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT is...